Healthcare / Medical DevicesNasdaqGM
$1.52
-0.04 (-2.56%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-39.1M · quality 53.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
38/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$151M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-86.8%
↓Gross Margin
49.8%
↑Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
+115.2%
FCF CAGR
—
FCF margin
-214.8%
FCF / Net income
0.82x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $13.6M · net income $-35.6M · FCF $-29.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | $13.6M | $13.6M | $12.9M | $11.0M | $6.8M | $1.5M | $294000.00 |
| Net Income | $-35.6M | $-35.6M | $-40.7M | $-44.2M | $-73.2M | $-64.9M | $-23.4M |
| EBITDA | $-36.0M | $-36.0M | $-42.2M | $-47.1M | $-72.9M | $-64.1M | $-23.2M |
| EPS | — | — | -0.56 | -0.62 | -1.04 | -17.57 | — |
| Gross Margin | 49.8% | 49.8% | 45.7% | 43.1% | 13.3% | -78.0% | -162.2% |
| Operating Margin | -273.4% | -273.4% | -335.3% | -436.1% | -1084.2% | -4336.1% | -7990.1% |
| Net Margin | -262.3% | -262.3% | -315.9% | -401.0% | -1073.7% | -4335.0% | -7968.4% |
| Balance Sheet | |||||||
| Debt/Equity | 0.01 | 0.01 | 0.01 | 0.00 | — | — | — |
| Current Ratio | 5.52 | 5.52 | — | — | — | — | — |
| Cash Flow | |||||||
| Free Cash Flow | $-29.1M | $-29.1M | $-39.1M | $-42.6M | $-72.9M | $-49.9M | $-23.1M |
| Returns | |||||||
| ROE | -86.8% | -86.8% | -83.0% | -52.4% | -59.1% | -34.8% | 38.4% |
| Valuation | |||||||
| P/B | 3.60 | 3.60 | 1.57 | 0.90 | 0.48 | — | — |
| Growth & Yield | |||||||
| Revenue Growth | 5.2% | 5.2% | 16.8% | 61.9% | — | 408.8% | — |
| EPS Growth | — | — | 9.7% | 40.4% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+152.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.56 → n/d
Residual
+152.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.